{"id":"https://openalex.org/W4200215773","doi":"https://doi.org/10.1200/jco.21.02067","title":"Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study","display_name":"Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study","alternate_titles":[],"publication_year":2021,"publication_date":"2021-12-21","ids":{"openalex":"https://openalex.org/W4200215773","doi":"https://doi.org/10.1200/jco.21.02067","pmid":"https://pubmed.ncbi.nlm.nih.gov/34932394","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8887945"},"language":"en","primary_location":{"id":"doi:10.1200/jco.21.02067","doi":"https://doi.org/10.1200/jco.21.02067","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.21.02067","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4200215773"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1200/jco.21.02067","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021359849","display_name":"David M. O\u2019Malley","orcid":"https://orcid.org/0000-0002-2828-0177","observed_orcids":["https://orcid.org/0000-0002-2828-0177"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]},{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"David M. O'Malley","raw_affiliation_strings":["Division of Gynecologic Oncology, The Ohio State University/James Comprehensive Cancer Center, Columbus, OH"],"raw_orcid":"https://orcid.org/0000-0002-2828-0177","affiliations":[{"raw_affiliation_string":"Division of Gynecologic Oncology, The Ohio State University/James Comprehensive Cancer Center, Columbus, OH","institution_ids":["https://openalex.org/I2799885155","https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Maryna Neffa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Maryna Neffa","raw_affiliation_strings":["CI of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection, Kharvik, Ukraine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CI of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection, Kharvik, Ukraine","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014611244","display_name":"Bradley J. Monk","orcid":"https://orcid.org/0000-0001-6985-0159","observed_orcids":["https://orcid.org/0000-0001-6985-0159"]},"institutions":[{"id":"https://openalex.org/I114493937","display_name":"Creighton University","ror":"https://ror.org/05wf30g94","country_code":"US","type":"education","lineage":["https://openalex.org/I114493937"]},{"id":"https://openalex.org/I138006243","display_name":"University of Arizona","ror":"https://ror.org/03m2x1q45","country_code":"US","type":"education","lineage":["https://openalex.org/I138006243"]},{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]},{"id":"https://openalex.org/I4210162453","display_name":"Arizona Oncology","ror":"https://ror.org/05c1xy536","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162453"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bradley J. Monk","raw_affiliation_strings":["Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ"],"raw_orcid":"https://orcid.org/0000-0002-0680-3184","affiliations":[{"raw_affiliation_string":"Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ","institution_ids":["https://openalex.org/I114493937","https://openalex.org/I138006243","https://openalex.org/I4210151469","https://openalex.org/I4210162453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tamar Melkadze","orcid":"https://orcid.org/0000-0003-0800-6514","observed_orcids":["https://orcid.org/0000-0003-0800-6514"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tamar Melkadze","raw_affiliation_strings":["Research Institute of Clinical Medicine, Tbilisi, Georgia"],"raw_orcid":"https://orcid.org/0000-0003-0800-6514","affiliations":[{"raw_affiliation_string":"Research Institute of Clinical Medicine, Tbilisi, Georgia","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Marilyn Huang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]},{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marilyn Huang","raw_affiliation_strings":["Division of Gynecologic Oncology, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Gynecologic Oncology, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL","institution_ids":["https://openalex.org/I145608581","https://openalex.org/I4210157065"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Anna Kryzhanivska","orcid":"https://orcid.org/0000-0001-7720-7374","observed_orcids":["https://orcid.org/0000-0001-7720-7374"]},"institutions":[{"id":"https://openalex.org/I1323554757","display_name":"Ivano-Frankivsk National Medical University","ror":"https://ror.org/023wxgq18","country_code":"UA","type":"education","lineage":["https://openalex.org/I1323554757"]}],"countries":["UA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anna Kryzhanivska","raw_affiliation_strings":["Regional Clinical Oncology Center, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine"],"raw_orcid":"https://orcid.org/0000-0001-7720-7374","affiliations":[{"raw_affiliation_string":"Regional Clinical Oncology Center, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine","institution_ids":["https://openalex.org/I1323554757"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Iurie Bulat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108897","display_name":"Institutul Oncologic din Republica Moldova","ror":"https://ror.org/01m92rg76","country_code":"MD","type":"healthcare","lineage":["https://openalex.org/I4210108897"]}],"countries":["MD"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Iurie Bulat","raw_affiliation_strings":["ARENSIA Exploratory Medicine Unit, Institute of Oncology, Chisinau, Moldova"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ARENSIA Exploratory Medicine Unit, Institute of Oncology, Chisinau, Moldova","institution_ids":["https://openalex.org/I4210108897"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073719611","display_name":"Tarek M. Meniawy","orcid":"https://orcid.org/0000-0002-1457-6137","observed_orcids":["https://orcid.org/0000-0002-1457-6137"]},"institutions":[{"id":"https://openalex.org/I4210156497","display_name":"Linear Clinical Research","ror":"https://ror.org/05vnpr825","country_code":"AU","type":"facility","lineage":["https://openalex.org/I4210156497"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tarek M. Meniawy","raw_affiliation_strings":["Linear Clinical Research, Nedlands, Australia"],"raw_orcid":"https://orcid.org/0000-0002-1457-6137","affiliations":[{"raw_affiliation_string":"Linear Clinical Research, Nedlands, Australia","institution_ids":["https://openalex.org/I4210156497"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Andrea Bagameri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100950","display_name":"Orsz\u00e1gos Idegseb\u00e9szeti Tudom\u00e1nyos Int\u00e9zet","ror":"https://ror.org/01b4q9c55","country_code":"HU","type":"healthcare","lineage":["https://openalex.org/I4210100950"]}],"countries":["HU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andrea Bagameri","raw_affiliation_strings":["Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zet, Budapest, Hungary"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zet, Budapest, Hungary","institution_ids":["https://openalex.org/I4210100950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028849312","display_name":"Wenge Wang","orcid":"https://orcid.org/0000-0001-9509-6735","observed_orcids":["https://orcid.org/0000-0001-9509-6735"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Edward W. Wang","raw_affiliation_strings":["Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Bernard Doger de Speville Uribe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210129357","display_name":"Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz","ror":"https://ror.org/049nvyb15","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210129357"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bernard Doger de Speville Uribe","raw_affiliation_strings":["START Madrid FJD, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"START Madrid FJD, Madrid, Spain","institution_ids":["https://openalex.org/I4210129357"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018564985","display_name":"Roberto Hegg","orcid":"https://orcid.org/0000-0002-6453-8155","observed_orcids":["https://orcid.org/0000-0002-6453-8155"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Roberto Hegg","raw_affiliation_strings":["Cl\u00ednica de Pesquisa e Centro de Estudos em Oncologia Ginecol\u00f3gica e Mam\u00e1ria, Sao Paulo, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cl\u00ednica de Pesquisa e Centro de Estudos em Oncologia Ginecol\u00f3gica e Mam\u00e1ria, Sao Paulo, Brazil","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Waldo Ortuzar Feliu","orcid":"https://orcid.org/0000-0003-0339-9216","observed_orcids":["https://orcid.org/0000-0003-0339-9216"]},"institutions":[{"id":"https://openalex.org/I2963242126","display_name":"Agenus (United States)","ror":"https://ror.org/03dwhj404","country_code":"US","type":"company","lineage":["https://openalex.org/I2963242126"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Waldo Ortuzar Feliu","raw_affiliation_strings":["Agenus Inc, Waltham, MA"],"raw_orcid":"https://orcid.org/0000-0003-0339-9216","affiliations":[{"raw_affiliation_string":"Agenus Inc, Waltham, MA","institution_ids":["https://openalex.org/I2963242126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048844031","display_name":"Marek Ancukiewicz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2963242126","display_name":"Agenus (United States)","ror":"https://ror.org/03dwhj404","country_code":"US","type":"company","lineage":["https://openalex.org/I2963242126"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marek Ancukiewicz","raw_affiliation_strings":["Agenus Inc, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Agenus Inc, Waltham, MA","institution_ids":["https://openalex.org/I2963242126"]}]},{"author_position":"last","author":{"id":null,"display_name":"Iwona Lugowska","orcid":"https://orcid.org/0000-0001-9511-178X","observed_orcids":["https://orcid.org/0000-0001-9511-178X"]},"institutions":[{"id":"https://openalex.org/I4210150880","display_name":"The Maria Sklodowska-Curie National Research Institute of Oncology","ror":"https://ror.org/04qcjsm24","country_code":"PL","type":"healthcare","lineage":["https://openalex.org/I4210150880"]}],"countries":["PL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Iwona Lugowska","raw_affiliation_strings":["Maria Sklodowska-Curie National Research Unit of Oncology, Warsaw, Poland"],"raw_orcid":"https://orcid.org/0000-0001-9511-178X","affiliations":[{"raw_affiliation_string":"Maria Sklodowska-Curie National Research Unit of Oncology, Warsaw, Poland","institution_ids":["https://openalex.org/I4210150880"]}]}],"institutions":[],"countries_distinct_count":7,"institutions_distinct_count":17,"corresponding_author_ids":["https://openalex.org/A5021359849"],"corresponding_institution_ids":["https://openalex.org/I2799885155","https://openalex.org/I52357470"],"apc_list":null,"apc_paid":null,"fwci":11.366,"has_fulltext":true,"cited_by_count":211,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.99306016,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":100},"biblio":{"volume":"40","issue":"7","first_page":"762","last_page":"771"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9487000107765198,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9487000107765198,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":0.039900001138448715,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10146","display_name":"Cervical Cancer and HPV Research","score":0.007499999832361937,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-cervical-cancer","display_name":"advanced cervical cancer","score":0.515999972820282},{"id":"https://openalex.org/keywords/balstilimab","display_name":"balstilimab","score":0.8830000162124634},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.7590000033378601},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":1.0},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7739999890327454},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.8880000114440918},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.875},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8379999995231628},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.8629999756813049},{"id":"https://openalex.org/keywords/squamous-cell-carcinoma","display_name":"squamous cell carcinoma","score":0.7549999952316284},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8790000081062317},{"id":"https://openalex.org/keywords/hypothyroidism","display_name":"hypothyroidism","score":0.9070000052452087},{"id":"https://openalex.org/keywords/hyperthyroidism","display_name":"hyperthyroidism","score":0.9900000095367432}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9038000106811523},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.7986000180244446},{"id":"https://openalex.org/C2778220009","wikidata":"https://www.wikidata.org/wiki/Q160105","display_name":"Cervical cancer","level":3,"score":0.4359000027179718},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41819998621940613},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41659998893737793},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.34220001101493835},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.33379998803138733},{"id":"https://openalex.org/C2780980858","wikidata":"https://www.wikidata.org/wiki/Q110022","display_name":"Dual (grammatical number)","level":2,"score":0.3334999978542328},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.33180001378059387},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.32820001244544983},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2791000008583069},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2766999900341034},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.272599995136261},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2702000141143799},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.259799987077713}],"mesh":[{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002583","descriptor_name":"Uterine Cervical Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002583","descriptor_name":"Uterine Cervical Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D002583","descriptor_name":"Uterine Cervical Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.1200/jco.21.02067","doi":"https://doi.org/10.1200/jco.21.02067","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.21.02067","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8887945","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8887945/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8887945/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Clin Oncol","raw_type":"Text"},{"id":"pmid:34932394","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34932394","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:repository.arizona.edu:10150/663817","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10150/663817","pdf_url":null,"source":{"id":"https://openalex.org/S4306400271","display_name":"UA Campus Repository (The University of Arizona)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I138006243","host_organization_name":"University of Arizona","host_organization_lineage":["https://openalex.org/I138006243"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Article"},{"id":"pmh:oai:ibn.idsi.md:151429","doi":null,"is_oa":true,"landing_page_url":"https://ibn.idsi.md/vizualizare_articol/151429","pdf_url":null,"source":null,"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of Clinical Oncology 762-771","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1200/jco.21.02067","doi":"https://doi.org/10.1200/jco.21.02067","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.21.02067","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G9000887552","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA016058","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4200215773.pdf","grobid_xml":"https://content.openalex.org/works/W4200215773.grobid-xml"},"referenced_works_count":45,"referenced_works":["https://openalex.org/W2019607817","https://openalex.org/W2100756525","https://openalex.org/W2136859769","https://openalex.org/W2138550445","https://openalex.org/W2166662937","https://openalex.org/W2263759961","https://openalex.org/W2344221521","https://openalex.org/W2441690768","https://openalex.org/W2511043440","https://openalex.org/W2547133566","https://openalex.org/W2553088533","https://openalex.org/W2586675028","https://openalex.org/W2727744877","https://openalex.org/W2742763599","https://openalex.org/W2753432434","https://openalex.org/W2770798942","https://openalex.org/W2784868445","https://openalex.org/W2785903627","https://openalex.org/W2792937256","https://openalex.org/W2795781326","https://openalex.org/W2804441916","https://openalex.org/W2887901772","https://openalex.org/W2889876566","https://openalex.org/W2895441403","https://openalex.org/W2896600825","https://openalex.org/W2900174742","https://openalex.org/W2914175256","https://openalex.org/W2915035020","https://openalex.org/W2925815206","https://openalex.org/W2943986328","https://openalex.org/W2952065098","https://openalex.org/W2974549300","https://openalex.org/W2976744492","https://openalex.org/W2977790547","https://openalex.org/W2993250673","https://openalex.org/W3036371943","https://openalex.org/W3040085298","https://openalex.org/W3043703771","https://openalex.org/W3100610731","https://openalex.org/W3124270777","https://openalex.org/W3155156689","https://openalex.org/W3162733280","https://openalex.org/W3163284774","https://openalex.org/W3193472415","https://openalex.org/W3194911083"],"related_works":["https://openalex.org/W4210692172","https://openalex.org/W3202681550","https://openalex.org/W3089334084","https://openalex.org/W3193472415","https://openalex.org/W3194911083","https://openalex.org/W4415942868","https://openalex.org/W3203581678","https://openalex.org/W3171051939","https://openalex.org/W4406138927","https://openalex.org/W4410636318"],"abstract_inverted_index":{"PURPOSE:":[0],"Balstilimab":[1],"(antiprogrammed":[2],"death-1)":[3],"and":[4,69,107,109,125,138,149,176,189,194,202,210,240,252,287],"zalifrelimab":[5,39,70,288],"(anticytotoxic":[6],"T-lymphocyte-associated":[7,271],"antigen-4)":[8],"are":[9],"two":[10],"new":[11],"checkpoint":[12],"inhibitors":[13],"emerging":[14],"as":[15],"promising":[16],"investigational":[17],"agents":[18],"for":[19,77],"the":[20,34,146,153,222,244,285],"treatment":[21],"of":[22,36,104,142,183,284],"advanced":[23,147],"cervical":[24,46,280],"cancer.":[25,281],"This":[26],"phase":[27],"II":[28],"trial":[29,264],"(ClinicalTrials.gov":[30],"identifier:":[31],"NCT03495882)":[32],"evaluated":[33],"combination":[35,289],"balstilimab":[37,62,128,286],"plus":[38,129],"in":[40,145,204,261,274,290],"patients":[41,132,151,205,217,275],"with":[42,61,127,180,206,218,256,276],"recurrent":[43,277],"and/or":[44,278],"metastatic":[45,279],"cancer":[47],"who":[48],"relapsed":[49],"after":[50],"prior":[51,140],"platinum-based":[52,143],"therapy.":[53],"PATIENTS":[54],"AND":[55],"METHODS:":[56],"Patients":[57],"were":[58,123,200,243],"intravenously":[59],"dosed":[60],"3":[63],"mg/kg":[64,72],"once":[65,73],"every":[66,74],"2":[67],"weeks":[68],"1":[71],"6":[75],"weeks,":[76],"up":[78],"to":[79,170,236,265],"24":[80],"months.":[81,161],"The":[82,156,162,198,226],"primary":[83],"end":[84,100],"point":[85],"was":[86,159,165,224,231,259],"objective":[87],"response":[88,184],"rate":[89,230],"(ORR,":[90],"RECIST":[91],"version":[92],"1.1,":[93],"assessed":[94],"by":[95],"independent":[96],"central":[97],"review).":[98],"Secondary":[99],"points":[101],"included":[102],"duration":[103,182],"response,":[105],"safety":[106],"tolerability,":[108,258],"survival.":[110],"RESULTS:":[111],"In":[112],"total,":[113],"155":[114],"women":[115],"(median":[116],"age,":[117],"50":[118],"years":[119],"[range,":[120],"24-76":[121],"years])":[122],"enrolled":[124],"treated":[126],"zalifrelimab;":[130],"125":[131],"had":[133],"measurable":[134],"disease":[135,228],"at":[136,191],"baseline":[137],"one":[139],"line":[141],"therapy":[144],"setting,":[148],"these":[150],"constituted":[152],"efficacy-evaluable":[154],"population.":[155],"median":[157,181],"follow-up":[158],"21":[160],"confirmed":[163],"ORR":[164,223],"25.6%":[166],"(95%":[167,233],"CI,":[168,234],"18.8":[169],"33.9),":[171],"including":[172],"10":[173],"complete":[174],"responders":[175],"22":[177],"partial":[178],"responders,":[179],"not":[185],"reached":[186],"(86.5%,":[187],"75.5%,":[188],"64.2%":[190],"6,":[192],"9,":[193],"12":[195],"months,":[196],"respectively).":[197],"ORRs":[199],"32.8%":[201],"9.1%":[203],"programmed":[207,211,269],"death":[208,212],"ligand-1-positive":[209],"ligand-1-negative":[213],"tumors,":[214],"respectively.":[215],"For":[216],"squamous":[219],"cell":[220],"carcinoma,":[221],"32.6%.":[225],"overall":[227],"control":[229],"52%":[232],"43.3":[235],"60.6).":[237],"Hypothyroidism":[238],"(14.2%)":[239],"hyperthyroidism":[241],"(7.1%)":[242],"most":[245],"common":[246],"immune-mediated":[247],"adverse":[248],"events.":[249],"CONCLUSION:":[250],"Promising":[251],"durable":[253],"clinical":[254],"activity,":[255],"favorable":[257],"seen":[260],"this":[262,291],"largest":[263],"date":[266],"evaluating":[267],"dual":[268],"death-1/cytotoxic":[270],"antigen-4":[272],"blockade":[273],"Further":[282],"investigation":[283],"setting":[292],"is":[293],"continuing.":[294]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4200215773","counts_by_year":[{"year":2026,"cited_by_count":32},{"year":2025,"cited_by_count":53},{"year":2024,"cited_by_count":51},{"year":2023,"cited_by_count":49},{"year":2022,"cited_by_count":25},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2021-12-31T00:00:00"}
